生命科学资讯

Alumis soars as TYK2 drug hits mark in psoriasis trials

Bright Minds' shares soar on positive Phase 2 seizure reduction data

Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

Amgen buys protein-degrading startup Dark Blue for up to $840M

Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference - PharmiWeb.com

A glycolytic shunt via the pentose phosphate pathway is a metabolic checkpoint for nervous system sensory homeostasis and axonal regeneration

Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors

Arrowhead takes aim at obesity market with early data on dual gene silencing assets

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs

Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator

Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact

Amgen to acquire Dark Blue Therapeutics for up to $840M

Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treat - PharmiWeb.com

From Young Researcher Award Finalist to International Collaborator: Two Visits to Promega

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech

Illumina launches cloud-based platform for multiomic data analysis - Investing.com

Roche's patent deal with Structure; AstraZeneca reports lupus data

Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal

Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference - BioSpace